<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutr J</journal-id><journal-id journal-id-type="iso-abbrev">Nutr J</journal-id><journal-title-group><journal-title>Nutrition Journal</journal-title></journal-title-group><issn pub-type="epub">1475-2891</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24889392</article-id><article-id pub-id-type="pmc">4055948</article-id><article-id pub-id-type="publisher-id">1475-2891-13-53</article-id><article-id pub-id-type="doi">10.1186/1475-2891-13-53</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Randomised controlled trial of the effects of L-ornithine on stress markers and sleep quality in healthy workers</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Miyake</surname><given-names>Mika</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>m-miyake@kirin.co.jp</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Kirisako</surname><given-names>Takayoshi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Takayoshi_Kirisako@kirin.co.jp</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Kokubo</surname><given-names>Takeshi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Takeshi_Kokubo@kirin.co.jp</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Miura</surname><given-names>Yutaka</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>yu-miura@kirin.co.jp</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Morishita</surname><given-names>Koji</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>koji.morishita@kyowa-kirin.co.jp</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Okamura</surname><given-names>Hisayoshi</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>okamura_hisayoshi@med.kurume-u.ac.jp</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Tsuda</surname><given-names>Akira</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>tsuda_akira@kurume-u.ac.jp</email></contrib></contrib-group><aff id="I1"><label>1</label>Research Laboratories for Health Science &#x00026; Food technologies, Research &#x00026; Development Division, Kirin Co., Ltd., 1-13-5, Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan</aff><aff id="I2"><label>2</label>Healthcare Products Development Center, Kyowa Hakko Bio Co., Ltd., 2, Miyukigaoka, Tsukuba, Ibaraki, 305&#x02013;0841, Japan</aff><aff id="I3"><label>3</label>Cognitive and molecular of Brain disease, Kurume University, 67, Asahi-machi, Kurume, Fukuoka 830-0011, Japan</aff><aff id="I4"><label>4</label>Department of Psychology, Kurume University, 1635, Miimachi, Kurume, Fukuoka 839-8502, Japan</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>3</day><month>6</month><year>2014</year></pub-date><volume>13</volume><fpage>53</fpage><lpage>53</lpage><history><date date-type="received"><day>8</day><month>1</month><year>2014</year></date><date date-type="accepted"><day>14</day><month>5</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Miyake et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Miyake et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.nutritionj.com/content/13/1/53"/><abstract><sec><title>Background</title><p>L-ornithine is a non-essential, non-protein amino acid. Although L-ornithine is contained in various foods, the amount is usually small.</p><p>Recently, studies have shown that orally administered L-ornithine reduced the stress response in animals.</p><p>From these findings, we speculated that L-ornithine may play a role in the relieve of stress and improve sleep and fatigue symptoms in humans. Through a randomised, double-blind, placebo-controlled clinical study, we asked if L-ornithine could be beneficial to stress and sleep in healthy workers.</p></sec><sec><title>Method</title><p>Fifty-two apparently healthy Japanese adults who had previously felt slight stress as well as fatigue were recruited to be study participants and were randomly divided into either the L-ornithine (400 mg/day) or placebo group. They orally consumed the respective test substance every day for 8 weeks. Serum was collected for the assessment of cortisol and dehydroepiandrosterone-sulphate (DHEA-S). Perceived mood and quality of sleep were measured by the Profile of Mood States (POMS), Athens Insomnia Scale (AIS), and Ogri-Shirakawa-Azumi sleep inventory MA version (OSA-MA).</p></sec><sec><title>Results</title><p>Serum cortisol levels and the cortisol/DHEA-S ratio were significantly decreased in the L-ornithine group in comparison with the placebo group. Also, anger was reduced and perceived sleep quality was improved in the L-ornithine group.</p></sec><sec><title>Conclusion</title><p>L-ornithine supplementation has the potential to relieve stress and improve sleep quality related to fatigue, both objectively and subjectively.</p></sec></abstract><kwd-group><kwd>L-ornithine supplementation</kwd><kwd>Stress and sleep</kwd><kwd>Clinical trial</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Sleep is both necessary and universal. Like eating and drinking, without it we will eventually die. Sleep is affected by various psychosocial factors, stress, and the daily routine, and it similarly affects all areas of life. Sleep is reported to be an important mediator of health through the autonomic nervous and immune systems and endocrine function
[<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Sleep and fatigue often correlate highly in cross-sectional studies, and reduced sleep duration involves the gradual accumulation of sleepiness/fatigue
[<xref ref-type="bibr" rid="B6">6</xref>]. Fatigue is generally considered to be important in daily life as it is closely related to quality of life and well being. Chronic or accumulated fatigue plays a role in an individual&#x02019;s performance of various functions. At worst, long-term accumulated fatigue can lead to <italic>karoshi</italic> (death from overwork)
[<xref ref-type="bibr" rid="B7">7</xref>]. Nevertheless, fatigue is a complex multidimensional concept that involves physical and psychosocial aspects. Psychological fatigue is closely associated with stress
[<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>].</p><p>Stress has been shown to induce a physiological response that is mediated by the hypothalamic-pituitary-adrenal (HPA) axis leading to the release of cortisol in humans and corticosterone in mice
[<xref ref-type="bibr" rid="B10">10</xref>]. Cortisol has long been used as a marker of stress
[<xref ref-type="bibr" rid="B11">11</xref>]. Dehydroepiandrosterone (DHEA) and its sulfate ester (DHEA-S) are the most abundant adrenal androgens. They are produced as precursors to the sex hormones estradiol and testosterone from adrenal glands and their serum levels decrease with age
[<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. DHEA-S has cortisol-lowering effects
[<xref ref-type="bibr" rid="B15">15</xref>] and may attenuate the adverse health effects of hypercortisolism
[<xref ref-type="bibr" rid="B16">16</xref>]. DHEA-to-cortisol ratios in serum and saliva are likely to be more reliable than concentrations of either hormone alone, with lower morning ratios seen in depression
[<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B19">19</xref>].</p><p>Recently it was reported that orally administered L-ornithine reduced restraint stress-induced activation of the HPA axis in mice accompanied by a reduction in the serum corticosterone concentration
[<xref ref-type="bibr" rid="B20">20</xref>]. It was shown that an intracerebroventricular (i.c.v.) injection of L-ornithine attenuated the stress response in neonatal chicks. These actions were suggested to be mediated by the gamma-aminobutyric acid (GABA) receptor.</p><p>From these findings, we speculated that L-ornithine may play a direct role in the central nervous system, relieve stress and improve sleep and fatigue symptoms in humans. L-ornithine is a non-essential, non-protein amino acid. Although L-ornithine is contained in various foods, the amount is usually small. Since ancient times, corbicula, a genus of the clam, has been considered to be good for the liver. They were found to contain 159.9 mg L-ornithine per 100 g of the extract
[<xref ref-type="bibr" rid="B21">21</xref>], which is high compared with other foods
[<xref ref-type="bibr" rid="B22">22</xref>] but still a relatively small amount.</p><p>Orally administered L-ornithine is transferred to the portal vein from the intestines and delivered to various tissues, such as the liver, kidney and muscle
[<xref ref-type="bibr" rid="B23">23</xref>]. In liver, L-ornithine plays a central role in the urea cycle which converts ammonia to urea
[<xref ref-type="bibr" rid="B24">24</xref>]. L-ornithine administration has been known to enhance detoxification of ammonia in the liver
[<xref ref-type="bibr" rid="B25">25</xref>].</p><p>Using a randomised, double-blind, placebo-controlled clinical trial, we evaluated the effect of long-term ingestion of L-ornithine on stress-related markers in serum and subjective feelings associated with stress and sleep in study subjects who indicated feelings of slight fatigue.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study design</title><p>This study was a randomised, double-blind and placebo-controlled trial. Subjects were randomly allocated to either the L-ornithine group or placebo group.</p><p>Most previous studies have evaluated the short term effect of L-ornithine supplementation on healthy volunteers
[<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]; we investigated the long term effect of L-ornithine supplementation on healthy volunteers. Eight weeks was chosen as the study period after consideration of the seasonal effect and the volunteer's burden.</p><p>Subjects ingested either L-ornithine or placebo capsules before going to bed every day for 8 weeks. Blood was collected four times during this clinical trial: before supplementation (0w), corresponding to the screening evaluation; 2 weeks (2w) and 4 weeks (4w) after taking the supplement; and at the end of the trial (8w).</p><p>We used the following three questionnaires to evaluate perceived stress, sleep quality and mood state: POMS
[<xref ref-type="bibr" rid="B28">28</xref>], Athens Insomnia Scale (AIS)
[<xref ref-type="bibr" rid="B29">29</xref>] and Ogri-Shirakawa-Azumi sleep inventory MA version (OSA-MA)
[<xref ref-type="bibr" rid="B30">30</xref>]. The POMS questionnaire is a well established, factor-analytically derived measure of psychological distress, such as mood, for which high levels of reliability and validity have been documented. We used the short-form POMS, which consists of thirty adjectives rated on a 0&#x02013;4 scale that can be consolidated into six mood scales: &#x0201c;tension-anxiety&#x0201d;, &#x0201c;depression-dejection&#x0201d;, &#x0201c;anger-hostility&#x0201d;, &#x0201c;vigor&#x0201d;, &#x0201c;fatigue&#x0201d; and &#x0201c;confusion&#x0201d;. The T score of the POMS questionnaire was calculated using the standard method
[<xref ref-type="bibr" rid="B28">28</xref>], showing that higher T scores represent high levels of distress, with the exception of &#x0201c;vigor&#x0201d;. This questionnaire was completed by each study participant at 0, 2, 4, 6 and 8 weeks.</p><p>The AIS is a useful tool to assess the existence of insomnia. This self-administered psychometric instrument consists of eight items: difficulty with sleep induction, awakening during the night, early morning awakening, total sleep time, overall quality of sleep, problems with sense of well-being, and functioning, and sleepiness during the day. Each item was rated on a scale of 0 to 3, with 0 corresponding to &#x0201c;no problem at all&#x0201d; and 3 indicating &#x0201c;a very serious problem&#x0201d;. Thus, the total AIS score ranges from 0 (denoting absence of any sleep-related problem) to 24 (representing the most severe degree of insomnia). Volunteers completed this questionnaire at 0, 4, and 8 weeks.</p><p>The OSA sleep inventory is popularly used for evaluation of sleep quality in Japan. The MA version is more useful for middle-aged and old-aged people and consists of sixteen adjectives with responses rated on a 0&#x02013;4 scale that can be consolidated into five factors: &#x0201c;sleepiness on rising&#x0201d;, &#x0201c;initiation and maintenance of sleep&#x0201d;, &#x0201c;frequent dreaming&#x0201d;, &#x0201c;refreshing&#x0201d; and &#x0201c;sleep length&#x0201d;. The OSA-MA score was calculated using an MS-Excel sheet
[<xref ref-type="bibr" rid="B30">30</xref>], with higher scores indicating a good quality of sleep: this questionnaire was completed weekly for 8 weeks.</p><p>The present study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects were approved by the local ethics committee of Medical Corporation, Akihabara Medical Clinic. Written informed consent was obtained from all participants.</p></sec><sec><title>Study population</title><p>Fifty-two apparently healthy Japanese individuals participated in this study. The volunteers ranged in age from 30 to 60 years (male: female ratio, 2:3), and had full-time jobs, excluding those who engaged in shift work or physical work, such as carpenter or delivery person, and irregular work schedules. Subjects were selected based on their POMS questionnaire score, which should be above 50 in T scores of &#x0201c;fatigue&#x0201d; and below 50 in T scores of &#x0201c;vigor&#x0201d;.</p><p>Smokers, pregnant or lactating women, or persons who habitually took L-ornithine, medication or supplements to improve stress, fatigue or sleep were excluded from this study. Also excluded were those with a past history of diabetes, hepatic disease, renal disease, hypertension, ischemic heart disease or abnormal glucose tolerance.</p></sec><sec><title>Test substance</title><p>L-Ornithine monohydrochloride and microcrystalline cellulose (FD-301) were purchased from Kyowa Hakko Bio (Tokyo, Japan) and Asahi Kasei Chemicals (Tokyo, Japan), respectively. Two kinds of small hard capsules were prepared, with one type of capsule containing 500 mg of L-ornithine monohydrochloride (400 mg L-ornithine) and 160 mg of microcrystalline cellulose per 2 capsules and the other (placebo) containing 560 mg of microcrystalline cellulose per 2 capsules.</p></sec><sec><title>Measurement of serum cortisol and DHEA-S</title><p>Participants were instructed not to eat breakfast after 8:00 am and abstain from smoking and caffeinated drinks prior to blood sampling. Blood samples were collected by venipuncture from all participants between 11:00 and 13:00. Serum cortisol and DHEAS levels were analyzed by commercial laboratories (BML Inc., Tokyo, Japan).</p></sec><sec><title>Statistical analysis</title><p>Values are presented as the mean&#x02009;&#x000b1;&#x02009;standard error (SEM). Two-way analysis of variance was used to evaluate the significance of differences between the placebo and L-ornithine groups followed by pairwise comparisons and unpaired <italic>t</italic> tests. <italic>P</italic> values less than 0.05 were considered to be statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Background information or demographic data</title><p>There were no statistical differences between the two groups at baseline (Table&#x000a0;
<xref ref-type="table" rid="T1">1</xref>). During the 8 study weeks of the study, no adverse events were observed.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Characteristics of subjects at 0 week</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="center"/><col align="center"/><col align="center"/><col align="right"/><col align="center"/><col align="right"/></colgroup><thead valign="top"><tr><th colspan="2" align="center">&#x000a0;</th><th colspan="2" align="center"><bold>Placebo group</bold></th><th colspan="2" align="center"><bold>Ornithine group</bold></th></tr></thead><tbody><tr><td colspan="2" align="center" valign="bottom">Men (n)<hr/></td><td colspan="2" align="center" valign="bottom">11<hr/></td><td colspan="2" align="center" valign="bottom">10<hr/></td></tr><tr><td colspan="2" align="center" valign="bottom">Women (n)<hr/></td><td colspan="2" align="center" valign="bottom">15<hr/></td><td colspan="2" align="center" valign="bottom">16<hr/></td></tr><tr><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">Average<hr/></td><td align="center" valign="bottom">SE<hr/></td><td align="center" valign="bottom">Average<hr/></td><td align="center" valign="bottom">SE<hr/></td></tr><tr><td colspan="2" align="center" valign="bottom">Age (years)<hr/></td><td align="center" valign="bottom">43.38<hr/></td><td align="center" valign="bottom">1.56<hr/></td><td align="center" valign="bottom">43.31<hr/></td><td align="center" valign="bottom">1.46<hr/></td></tr><tr><td rowspan="6" align="center" valign="top">POMS<hr/></td><td align="center" valign="bottom">Tension-anxiety<hr/></td><td align="center" valign="bottom">63.35<hr/></td><td align="center" valign="bottom">1.66<hr/></td><td align="center" valign="bottom">65.23<hr/></td><td align="center" valign="bottom">1.99<hr/></td></tr><tr><td align="center" valign="bottom">Depression-dejection<hr/></td><td align="center" valign="bottom">65.69<hr/></td><td align="center" valign="bottom">2.32<hr/></td><td align="center" valign="bottom">64.19<hr/></td><td align="center" valign="bottom">2.26<hr/></td></tr><tr><td align="center" valign="bottom">Anger-hostility<hr/></td><td align="center" valign="bottom">61.85<hr/></td><td align="center" valign="bottom">2.29<hr/></td><td align="center" valign="bottom">63.31<hr/></td><td align="center" valign="bottom">2.28<hr/></td></tr><tr><td align="center" valign="bottom">Vigor<hr/></td><td align="center" valign="bottom">35.62<hr/></td><td align="center" valign="bottom">1.05<hr/></td><td align="center" valign="bottom">36.88<hr/></td><td align="center" valign="bottom">1.12<hr/></td></tr><tr><td align="center" valign="bottom">Fatigue<hr/></td><td align="center" valign="bottom">66.96<hr/></td><td align="center" valign="bottom">1.26<hr/></td><td align="center" valign="bottom">68.77<hr/></td><td align="center" valign="bottom">1.28<hr/></td></tr><tr><td align="center" valign="bottom">Confusion<hr/></td><td align="center" valign="bottom">68.31<hr/></td><td align="center" valign="bottom">1.85<hr/></td><td align="center" valign="bottom">69.77<hr/></td><td align="center" valign="bottom">1.92<hr/></td></tr><tr><td colspan="2" align="center" valign="bottom">AIS<hr/></td><td align="center" valign="bottom">7.96<hr/></td><td align="center" valign="bottom">0.61<hr/></td><td align="center" valign="bottom">8.54<hr/></td><td align="center" valign="bottom">0.54<hr/></td></tr><tr><td rowspan="5" align="center" valign="top">OSA<hr/></td><td align="center" valign="bottom">Sleepiness on rising<hr/></td><td align="center" valign="bottom">9.37<hr/></td><td align="center" valign="bottom">0.87<hr/></td><td align="center" valign="bottom">7.98<hr/></td><td align="center" valign="bottom">1.10<hr/></td></tr><tr><td align="center" valign="bottom">Initiation and maintenance of sleep<hr/></td><td align="center" valign="bottom">15.21<hr/></td><td align="center" valign="bottom">1.34<hr/></td><td align="center" valign="bottom">12.12<hr/></td><td align="center" valign="bottom">1.17<hr/></td></tr><tr><td align="center" valign="bottom">Frequent dreaming<hr/></td><td align="center" valign="bottom">21.73<hr/></td><td align="center" valign="bottom">1.62<hr/></td><td align="center" valign="bottom">23.04<hr/></td><td align="center" valign="bottom">1.40<hr/></td></tr><tr><td align="center" valign="bottom">Refreshing<hr/></td><td align="center" valign="bottom">10.92<hr/></td><td align="center" valign="bottom">1.09<hr/></td><td align="center" valign="bottom">10.27<hr/></td><td align="center" valign="bottom">0.88<hr/></td></tr><tr><td align="center" valign="bottom">Sleep length<hr/></td><td align="center" valign="bottom">13.31<hr/></td><td align="center" valign="bottom">1.11<hr/></td><td align="center" valign="bottom">14.71<hr/></td><td align="center" valign="bottom">1.40<hr/></td></tr><tr><td colspan="2" align="center" valign="bottom">Cortisol (&#x003bc;M)<hr/></td><td align="center" valign="bottom">0.21<hr/></td><td align="center" valign="bottom">0.02<hr/></td><td align="center" valign="bottom">0.23<hr/></td><td align="center" valign="bottom">0.01<hr/></td></tr><tr><td colspan="2" align="center" valign="bottom">DHEA-S (&#x003bc;M)<hr/></td><td align="center" valign="bottom">4.25<hr/></td><td align="center" valign="bottom">0.32<hr/></td><td align="center" valign="bottom">4.72<hr/></td><td align="center" valign="bottom">0.44<hr/></td></tr><tr><td colspan="2" align="center">Cortisol/DHEA-S &#x000d7; 100</td><td align="center">5.22</td><td align="center">0.40</td><td align="center">5.67</td><td align="center">0.56</td></tr></tbody></table></table-wrap><p>Most of the study subjects were general office workers with 24 out of 26 participants in the placebo group, and 23 out of 26 participants in the L-ornithine group.</p></sec><sec><title>L-Ornithine supplementation improved mood state in study participants</title><p>Changes in POMS scores are shown in Figure&#x000a0;
<xref ref-type="fig" rid="F1">1</xref>. There was a trend toward an improved mood indicated by each score compared to 0 weeks but there was no significant difference between the two groups. There was a significant improvement in self-reported &#x0201c;anger-hostility&#x0201d; at 2 weeks and 6 weeks in the L-ornithine group compared to the placebo group (Figure&#x000a0;
<xref ref-type="fig" rid="F1">1</xref>C).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Effect of L-ornithine supplementation on POMS.</bold> Means of the change from 0 weeks of each POMS score (<bold>A</bold>, tension-anxiety; <bold>B</bold>, depression-dejection; <bold>C</bold>, anger-hostility; <bold>D</bold>, vigor; <bold>E</bold>, fatigue; <bold>F</bold>, confusion) to 2, 4, 6 and 8 weeks: mean&#x02009;&#x000b1;&#x02009;SE. White circles (&#x025cb;) indicate the placebo and black circles (&#x025cf;) indicate L-ornithine.</p></caption><graphic xlink:href="1475-2891-13-53-1"/></fig></sec><sec><title>L-Ornithine supplementation improved sleep quality in study participants</title><p>As shown in Figure&#x000a0;
<xref ref-type="fig" rid="F2">2</xref>, the AIS score revealed a trend towards improved insomnia in both groups from 0 weeks to 8 weeks. Furthermore, the AIS score indicated significant improvement in the L-ornithine group at 4 weeks in comparison with the placebo group.Scores for the OSA-MA for each group over an 8-week period are shown in Figure&#x000a0;
<xref ref-type="fig" rid="F3">3</xref>. Scores of three OSA-MA items, &#x0201c;sleepiness on rising&#x0201d; (Figure&#x000a0;
<xref ref-type="fig" rid="F3">3</xref>A), &#x0201c;initiation and maintenance of sleep&#x0201d; (Figure&#x000a0;
<xref ref-type="fig" rid="F3">3</xref>B) and &#x0201c;refreshing&#x0201d; (Figure&#x000a0;
<xref ref-type="fig" rid="F3">3</xref>D), tended towards improved sleep quality in both groups without significant between-group differences. Scores for &#x0201c;frequent dreaming&#x0201d; (Figure&#x000a0;
<xref ref-type="fig" rid="F3">3</xref>C) and &#x0201c;sleep length&#x0201d; (Figure&#x000a0;
<xref ref-type="fig" rid="F3">3</xref>E) were unchanged in the placebo group, however, the score for the L-ornithine group significantly improved for self-reported &#x0201c;initiation and maintenance of sleep&#x0201d; (Figure&#x000a0;
<xref ref-type="fig" rid="F3">3</xref>B) at 4 weeks and &#x0201c;sleep length&#x0201d; (Figure&#x000a0;
<xref ref-type="fig" rid="F3">3</xref>E) at 5 to 7 weeks in comparison with the placebo group.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Effect of L-ornithine supplementation on AIS.</bold> Means of the change from 0 weeks of each AIS score to 4 and 8 weeks: mean&#x02009;&#x000b1;&#x02009;SE. White circles (&#x025cb;) indicate the placebo and black circles (&#x025cf;) indicate L-ornithine.</p></caption><graphic xlink:href="1475-2891-13-53-2"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Effect of L-ornithine supplementation on OSA.</bold> Means of the change from 0 weeks of each OSA score (<bold>A</bold>, sleepiness on rising; <bold>B</bold>, initiation and maintenance of sleep; <bold>C</bold>, frequent dreaming; <bold>D</bold>, refreshing; <bold>E</bold>, sleep length) to 1, 2, 3, 4, 5, 6, 7 and 8 weeks: mean&#x02009;&#x000b1;&#x02009;SE. White circles (&#x025cb;) indicate the placebo and black circles (&#x025cf;) indicate L-ornithine.</p></caption><graphic xlink:href="1475-2891-13-53-3"/></fig></sec><sec><title>L-Ornithine supplementation attenuated the serum cortisol/DHEA-S molar ratio in study participants</title><p>While the concentration of serum DHEA-S was not increased by L-ornithine intake, serum cortisol concentration decreased in the L-ornithine group. Although the change in either level did not differ significantly between the two groups at any examination point (Figure&#x000a0;
<xref ref-type="fig" rid="F4">4</xref>A,
<xref ref-type="fig" rid="F4">4</xref>B), the change in cortisol/DHEA-S ratio significantly decreased in the L-ornithine group after 4 weeks (Figure&#x000a0;
<xref ref-type="fig" rid="F4">4</xref>C). The cortisol/DHEA-S (&#x000d7;100) ratio was calculated based on serum cortisol and DHEA-S concentrations.</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>Effect of L-ornithine supplementation on serum stress markers.</bold> Means of the change from 0 weeks of each stress marker level (<bold>A</bold>, DHEA-S; <bold>B</bold>, cortisol; <bold>C</bold>, cortisol/DHEA-S) to 2, 4, and 8 weeks: mean&#x02009;&#x000b1;&#x02009;SE. White circles (&#x025cb;) indicate the placebo and black circles (&#x025cf;) indicate L-ornithine.</p></caption><graphic xlink:href="1475-2891-13-53-4"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Our results showed that L-ornithine supplementation had a favourable effect on the cortisol response as an objective stress marker and improved perceived mood and sleep quality related to fatigue as well as subjective feelings derived from stress.</p><p>Previous studies reported that i.c.v. injections of L-ornithine had sedative and hypnotic effects on neonatal chicks exposed to acute stressful conditions
[<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. That action was mediated by GABA<sub>A</sub> receptors. It was also confirmed that orally administered L-ornithine can be transported into the brain of mice
[<xref ref-type="bibr" rid="B20">20</xref>], and as a result, reduced the plasma corticosterone concentration induced by restraint stress in mice. L-ornithine levels in the brain increased after oral administration of L-ornithine in mice
[<xref ref-type="bibr" rid="B20">20</xref>]. Moreover, it was shown that i.c.v. injected L-arginine, the precursor of L-ornithine, increased both L-arginine and L-ornithine concentrations in the telencephalon and diencephalon in chicks 10 min post-injection
[<xref ref-type="bibr" rid="B33">33</xref>], however, the GABA content was not changed. This suggests that the sedative and hypnotic effects of L-ornithine were not due to changes in GABA synthesis
[<xref ref-type="bibr" rid="B32">32</xref>].</p><p>The role of GABA in HPA axis regulation has been well established, indicating that corticotropin-releasing hormone (CHR) neurons receive robust GABAergic inhibition
[<xref ref-type="bibr" rid="B34">34</xref>]. In addition, micro infusion of GABA agonists, such as the stress-derived neurosteroid tetrahydrodeoxycorticosterone (THDOC), into the paraventricular nucleus (PVN) decreased circulating levels of stress hormones
[<xref ref-type="bibr" rid="B35">35</xref>]. Our result showing that orally administered L-ornithine decreased the serum cortisol level in human subjects was in agreement with previous animal studies on the effectiveness of stress reduction through the alleviation of HPA axis hyperactivity
[<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B31">31</xref>-<xref ref-type="bibr" rid="B34">34</xref>].</p><p>We observed that L-ornithine supplementation for 8 weeks reduced the serum cortisol level and cortisol/DHEA-S ratio, mainly due to reduction in the cortisol level. An imbalance between cortisol and DHEA-S may be a key factor in physical and psychiatric disease
[<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>]. The molar DHEA-S/cortisol ratio was shown to be significantly lower in non-medicated depressed patients than in control subjects, and evening salivary DHEA/cortisol ratios were inversely correlated with the length of the current depressive episode
[<xref ref-type="bibr" rid="B38">38</xref>]. Elevated cortisol/DHEA-S ratios in schizophrenia patients were positively associated with higher scores for anxiety and anger, depression and hostility, age, age at onset of illness, and duration of illness
[<xref ref-type="bibr" rid="B39">39</xref>].</p><p>These reports provide support for our results showing that the decrease in cortisol/DHEA-S ratios through the administration of L-ornithine corresponded to the improvement in mood related to &#x0201c;anger-hostility&#x0201d; as well as sleep quality.</p><p>The initial decreasing tendency of the cortisol/DHEA-S ratios in the placebo group may be due to a non-specific, natural change which occurs after formal ornithine and placebo intake treatments. It is widely accepted that on average, brief initial interventions yield outcomes similar to those with prolonged treatments, suggesting that changes could be triggered after a brief phase of treatment
[<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B41">41</xref>].</p><p>&#x0201c;Anger-hostility&#x0201d;, an item on the POMS, is one of the phenotypes resulting from activation of sympathetic nerves. A physiological change accompanying stress was shown to be the increased excretion of cortisol and adrenaline
[<xref ref-type="bibr" rid="B42">42</xref>]. Adrenalin promotes activation of the sympathetic nerve system suggesting L-ornithine supplementation might affect, not only the HPA axis, but also the autonomic nervous system. Unfortunately, we did not examine whether L-ornithine supplementation could affect either the autonomic nervous system or adrenaline levels.</p><p>Our results also suggested that sleep quality was improved by L-ornithine, as revealed by both AIS and OSA-MA questionnaires, along with alleviation of stress (cortisol/DHEA-S). The present finding is in accordance with a previous report that L-ornithine supplementation after alcohol consumption improved sleep quality as perceived upon awakening in flushers
[<xref ref-type="bibr" rid="B43">43</xref>] and that ornithine increased the amount of non-rapid eye movement (NREM) sleep without reducing the power spectrum density of NREM sleep in mice
[<xref ref-type="bibr" rid="B44">44</xref>]. This result replicated findings of our previous study, that ornithine could improve sleep in an animal model and suggested the effectiveness of orally administered L-ornithine on stress reduction through improvement of sleep quality in human subjects.</p><p>Furthermore, it was shown that L-ornithine administration stimulated release of growth hormone
[<xref ref-type="bibr" rid="B45">45</xref>,<xref ref-type="bibr" rid="B46">46</xref>], which is secreted as the largest pulse after the onset of sleep, and that there is a correlation between night-time growth hormone release and sleep satisfaction
[<xref ref-type="bibr" rid="B47">47</xref>-<xref ref-type="bibr" rid="B49">49</xref>].</p><p>A serotonin metabolite (5-hydroxyindole acetic acid, 5-HIAA) was induced in the striatum after L-ornithine supplementation
[<xref ref-type="bibr" rid="B20">20</xref>]. Day-time serotonin levels stimulate production of melatonin during the night
[<xref ref-type="bibr" rid="B50">50</xref>-<xref ref-type="bibr" rid="B52">52</xref>], therefore, L-ornithine might be considered an important nutrient to maintain the circadian rhythm and to allow individuals to sleep well.</p><p>Job stress is one of the most important social problems for workers today. This study has provided further objective evidence of the usefulness and effectiveness of L-ornithine for managing stress and sleep quality related to fatigue. Future studies must address how L-ornithine affects regulation of blood glucose and the autonomic nervous system.</p><p>Limitations exist in this study: first, we did not evaluate plasma ornithine levels, so we were unable to assess any direct correlation between ornithine and suppressing stress markers or improved subjective feelings. Second, we used three tests to assess fatigue and mood states, however, many tests, using differing strategies, are required to properly evaluate psychological status. Third, we determined the sample size of this study on the basis of a previous report
[<xref ref-type="bibr" rid="B26">26</xref>], however, this sample size (n&#x02009;=&#x02009;26) was not sufficient to lead to draw firm conclusions and more extensive studies are needed to confirm our findings.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>L-ornithine plays a central role in the urea cycle which converts ammonia to urea in the liver. L-ornithine administration has been known to enhance detoxification of ammonia in the liver. Recent reports have shown that L-ornithine has a positive effect on animal stress models. Our study suggested that L-ornithine has a positive effect on stress and sleep in healthy workers. L-ornithine might be beneficial for people who live a stressful life.</p></sec><sec><title>Abbreviations</title><p>DHEA-S: Dehydroepiandrosterone-sulphate; DHEA: Dehydroepiandrosterone; POMS: Profile of Mood States; AIS: Athens Insomnia Scale; OSA-MA: Ogri-Shirakawa-Azumi sleep inventory MA version; HPA: Hypothalamic-pituitary-adrenal; GABA: Gamma-aminobutyric acid; CHR: Corticotropin-releasing hormone; THDOC: Tetrahydrodeoxycorticosterone; PVN: Paraventricular nucleus; NREM: Non-rapid eye movement; 5-HIAA: 5-hydroxyindole acetic acid.</p></sec><sec><title>Competing interests</title><p>In this study, we used L-ornithine monohydrochloride, a product of Kyowa Hakko Bio Company, Limited. This company is an affiliate of Kirin Company, Limited, to which the authors belong. None of the authors had a personal or financial conflict of interest.</p></sec><sec><title>Authors&#x02019; contributions</title><p>MM was involved in designing the trial, writing the trial protocol, calculating the sample size, analysing data, drafting and finalising the manuscript. TKo, TKi and YM were involved in designing the trial, writing the trial protocol, supervising analysis of data, and drafting and revising the manuscript. MK was involved in designing the trial. AT and HO supervised the trial as the principal investigator and participated in drafting and revising the manuscript. All authors contributed to the data interpretation and approved the final version of the manuscript.</p></sec></body><back><sec><title>Financial support</title><p>This study was provided by Kirin Co., Ltd and Kyowa Hakko Bio Co., Ltd.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>S</given-names></name><name><surname>Doyle</surname><given-names>WJ</given-names></name><name><surname>Alper</surname><given-names>CM</given-names></name><name><surname>Janicki-Deverts</surname><given-names>D</given-names></name><name><surname>Turner</surname><given-names>RB</given-names></name><article-title>Sleep habits and susceptibility to the common cold</article-title><source>Arch Intern Med</source><year>2009</year><volume>169</volume><fpage>62</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1001/archinternmed.2008.505</pub-id><pub-id pub-id-type="pmid">19139325</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Sakami</surname><given-names>S</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Kawakami</surname><given-names>N</given-names></name><name><surname>Haratani</surname><given-names>T</given-names></name><name><surname>Fukui</surname><given-names>A</given-names></name><name><surname>Kobayashi</surname><given-names>F</given-names></name><name><surname>Fujita</surname><given-names>O</given-names></name><name><surname>Araki</surname><given-names>S</given-names></name><name><surname>Kawamura</surname><given-names>N</given-names></name><article-title>Coemergence of insomnia and a shift in the Th1/Th2 balance toward Th2 dominance</article-title><source>Neuroimmunomodulation</source><year>2002</year><volume>10</volume><fpage>337</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1159/000071474</pub-id><pub-id pub-id-type="pmid">12907840</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Savard</surname><given-names>J</given-names></name><name><surname>Laroche</surname><given-names>L</given-names></name><name><surname>Simard</surname><given-names>S</given-names></name><name><surname>Ivers</surname><given-names>H</given-names></name><name><surname>Morin</surname><given-names>CM</given-names></name><article-title>Chronic insomnia and immune functioning</article-title><source>Psychosom Med</source><year>2003</year><volume>65</volume><fpage>211</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1097/01.PSY.0000033126.22740.F3</pub-id><pub-id pub-id-type="pmid">12651988</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Hachul</surname><given-names>H</given-names></name><name><surname>Bittencourt</surname><given-names>LR</given-names></name><name><surname>Andersen</surname><given-names>ML</given-names></name><name><surname>Haidar</surname><given-names>MA</given-names></name><name><surname>Baracat</surname><given-names>EC</given-names></name><name><surname>Tufik</surname><given-names>S</given-names></name><article-title>Effects of hormone therapy with estrogen and/or progesterone on sleep pattern in postmenopausal women</article-title><source>Int J Gynaecol Obstet</source><year>2008</year><volume>103</volume><fpage>207</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.ijgo.2008.07.009</pub-id><pub-id pub-id-type="pmid">18812241</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Irwin</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>C</given-names></name><name><surname>Kennedy</surname><given-names>B</given-names></name><name><surname>Christian Gillin</surname><given-names>J</given-names></name><name><surname>Ziegler</surname><given-names>M</given-names></name><article-title>Nocturnal catecholamines and immune function in insomniacs, depressed patients, and control subjects</article-title><source>Brain Behav Immun</source><year>2003</year><volume>17</volume><fpage>365</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1016/S0889-1591(03)00031-X</pub-id><pub-id pub-id-type="pmid">12946658</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Akerstedt</surname><given-names>T</given-names></name><name><surname>Kecklund</surname><given-names>G</given-names></name><name><surname>Selen</surname><given-names>J</given-names></name><article-title>Disturbed sleep and fatigue as predictors of return from long-term sickness absence</article-title><source>Ind Health</source><year>2010</year><volume>48</volume><fpage>209</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.2486/indhealth.48.209</pub-id><pub-id pub-id-type="pmid">20424352</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Nishiyama</surname><given-names>K</given-names></name><name><surname>Johnson</surname><given-names>JV</given-names></name><article-title>Karoshi&#x02013;death from overwork: occupational health consequences of Japanese production management</article-title><source>Int J Health Serv</source><year>1997</year><volume>27</volume><fpage>625</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.2190/1JPC-679V-DYNT-HJ6G</pub-id><pub-id pub-id-type="pmid">9399110</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Ha</surname><given-names>M</given-names></name><name><surname>Yi</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><article-title>Subjective fatigue and stress hormone levels in urine according to duration of shiftwork</article-title><source>J Occup Health</source><year>2006</year><volume>48</volume><fpage>446</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1539/joh.48.446</pub-id><pub-id pub-id-type="pmid">17179637</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>DL</given-names></name><name><surname>Tanigawa</surname><given-names>T</given-names></name><name><surname>Weiss</surname><given-names>SM</given-names></name><article-title>Stress management and workplace disability in the US, Europe and Japan</article-title><source>J Occup Health</source><year>2003</year><volume>45</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1539/joh.45.1</pub-id><pub-id pub-id-type="pmid">14605422</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Mody</surname><given-names>I</given-names></name><name><surname>Maguire</surname><given-names>J</given-names></name><article-title>The reciprocal regulation of stress hormones and GABA(A) receptors</article-title><source>Front Cell Neurosci</source><year>2012</year><volume>6</volume><fpage>4</fpage><pub-id pub-id-type="pmid">22319473</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Levine</surname><given-names>A</given-names></name><name><surname>Zagoory-Sharon</surname><given-names>O</given-names></name><name><surname>Feldman</surname><given-names>R</given-names></name><name><surname>Lewis</surname><given-names>JG</given-names></name><name><surname>Weller</surname><given-names>A</given-names></name><article-title>Measuring cortisol in human psychobiological studies</article-title><source>Physiol Behav</source><year>2007</year><volume>90</volume><fpage>43</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.physbeh.2006.08.025</pub-id><pub-id pub-id-type="pmid">17055006</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Morley</surname><given-names>JE</given-names></name><name><surname>Kaiser</surname><given-names>F</given-names></name><name><surname>Raum</surname><given-names>WJ</given-names></name><name><surname>Perry</surname><given-names>HM</given-names><suffix>3rd</suffix></name><name><surname>Flood</surname><given-names>JF</given-names></name><name><surname>Jensen</surname><given-names>J</given-names></name><name><surname>Silver</surname><given-names>AJ</given-names></name><name><surname>Roberts</surname><given-names>E</given-names></name><article-title>Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone</article-title><source>Proc Natl Acad Sci U S A</source><year>1997</year><volume>94</volume><fpage>7537</fpage><lpage>7542</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.14.7537</pub-id><pub-id pub-id-type="pmid">9207127</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Nafziger</surname><given-names>AN</given-names></name><name><surname>Bowlin</surname><given-names>SJ</given-names></name><name><surname>Jenkins</surname><given-names>PL</given-names></name><name><surname>Pearson</surname><given-names>TA</given-names></name><article-title>Longitudinal changes in dehydroepiandrosterone concentrations in men and women</article-title><source>J Lab Clin Med</source><year>1998</year><volume>131</volume><fpage>316</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/S0022-2143(98)90181-0</pub-id><pub-id pub-id-type="pmid">9579384</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Binello</surname><given-names>E</given-names></name><name><surname>Gordon</surname><given-names>CM</given-names></name><article-title>Clinical uses and misuses of dehydroepiandrosterone</article-title><source>Curr Opin Pharmacol</source><year>2003</year><volume>3</volume><fpage>635</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2003.07.006</pub-id><pub-id pub-id-type="pmid">14644016</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Kroboth</surname><given-names>PD</given-names></name><name><surname>Amico</surname><given-names>JA</given-names></name><name><surname>Stone</surname><given-names>RA</given-names></name><name><surname>Folan</surname><given-names>M</given-names></name><name><surname>Frye</surname><given-names>RF</given-names></name><name><surname>Kroboth</surname><given-names>FJ</given-names></name><name><surname>Bigos</surname><given-names>KL</given-names></name><name><surname>Fabian</surname><given-names>TJ</given-names></name><name><surname>Linares</surname><given-names>AM</given-names></name><name><surname>Pollock</surname><given-names>BG</given-names></name><name><surname>Hakala</surname><given-names>C</given-names></name><article-title>Influence of DHEA administration on 24-hour cortisol concentrations</article-title><source>J Clin Psychopharmacol</source><year>2003</year><volume>23</volume><fpage>96</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1097/00004714-200302000-00014</pub-id><pub-id pub-id-type="pmid">12544381</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Bauer</surname><given-names>ME</given-names></name><article-title>Chronic stress and immunosenescence: a review</article-title><source>Neuroimmunomodulation</source><year>2008</year><volume>15</volume><fpage>241</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1159/000156467</pub-id><pub-id pub-id-type="pmid">19047801</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Michael</surname><given-names>A</given-names></name><name><surname>Jenaway</surname><given-names>A</given-names></name><name><surname>Paykel</surname><given-names>ES</given-names></name><name><surname>Herbert</surname><given-names>J</given-names></name><article-title>Altered salivary dehydroepiandrosterone levels in major depression in adults</article-title><source>Biol Psychiatry</source><year>2000</year><volume>48</volume><fpage>989</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(00)00955-0</pub-id><pub-id pub-id-type="pmid">11082473</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Osran</surname><given-names>H</given-names></name><name><surname>Reist</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>CC</given-names></name><name><surname>Lifrak</surname><given-names>ET</given-names></name><name><surname>Chicz-DeMet</surname><given-names>A</given-names></name><name><surname>Parker</surname><given-names>LN</given-names></name><article-title>Adrenal androgens and cortisol in major depression</article-title><source>Am J Psychiatry</source><year>1993</year><volume>150</volume><fpage>806</fpage><lpage>809</lpage><pub-id pub-id-type="pmid">8386908</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Young</surname><given-names>AH</given-names></name><name><surname>Gallagher</surname><given-names>P</given-names></name><name><surname>Porter</surname><given-names>RJ</given-names></name><article-title>Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients</article-title><source>Am J Psychiatry</source><year>2002</year><volume>159</volume><fpage>1237</fpage><lpage>1239</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.159.7.1237</pub-id><pub-id pub-id-type="pmid">12091208</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Kurata</surname><given-names>K</given-names></name><name><surname>Nagasawa</surname><given-names>M</given-names></name><name><surname>Tomonaga</surname><given-names>S</given-names></name><name><surname>Aoki</surname><given-names>M</given-names></name><name><surname>Akiduki</surname><given-names>S</given-names></name><name><surname>Morishita</surname><given-names>K</given-names></name><name><surname>Denbow</surname><given-names>DM</given-names></name><name><surname>Furuse</surname><given-names>M</given-names></name><article-title>Orally administered L-ornithine reduces restraint stress-induced activation of the hypothalamic-pituitary-adrenal axis in mice</article-title><source>Neurosci Lett</source><year>2012</year><volume>506</volume><fpage>287</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2011.11.024</pub-id><pub-id pub-id-type="pmid">22133808</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Uchisawa</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>A</given-names></name><name><surname>Ichita</surname><given-names>J</given-names></name><name><surname>Matsue</surname><given-names>H</given-names></name><name><surname>Ono</surname><given-names>T</given-names></name><article-title>Influence of low-temperature processing of the brackish-water bivalve, Corbicula japonica, on the ornithine content of its extract</article-title><source>Biosci Biotechnol Biochem</source><year>2004</year><volume>68</volume><fpage>1228</fpage><lpage>1234</lpage><pub-id pub-id-type="doi">10.1271/bbb.68.1228</pub-id><pub-id pub-id-type="pmid">15215585</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Shiau</surname><given-names>C</given-names></name><article-title>Proximate composition, free amino acids and peptides contents in commercial chicken and other meat essences</article-title><source>J Food Drug Anal</source><year>2002</year><volume>10</volume><fpage>170</fpage><lpage>177</lpage></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Vaubourdolle</surname><given-names>M</given-names></name><name><surname>Jardel</surname><given-names>A</given-names></name><name><surname>Coudray-Lucas</surname><given-names>C</given-names></name><name><surname>Ekindjian</surname><given-names>OG</given-names></name><name><surname>Agneray</surname><given-names>J</given-names></name><name><surname>Cynober</surname><given-names>L</given-names></name><article-title>Fate of enterally administered ornithine in healthy animals: interactions with alpha-ketoglutarate</article-title><source>Nutrition</source><year>1989</year><volume>5</volume><fpage>183</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">2520285</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="book"><name><surname>Rodwell</surname><given-names>V</given-names></name><person-group person-group-type="editor">Murray R, Mayes P, Rodwell V, Granner D</person-group><article-title>Catabolism of Proteins and of Amino Acid Nitrogen</article-title><source>Herper's Biochemistry. Chapter 31</source><year>1999</year><edition>25</edition><publisher-name>New York: McGraw-Hill/Appleton &#x00026; Lange</publisher-name><fpage>313</fpage><lpage>322</lpage></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Krebs</surname><given-names>HA</given-names></name><name><surname>Hems</surname><given-names>R</given-names></name><name><surname>Lund</surname><given-names>P</given-names></name><article-title>Accumulation of amino acids by the perfused rat liver in the presence of ethanol</article-title><source>Biochem J</source><year>1973</year><volume>134</volume><fpage>697</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">4749270</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Sugino</surname><given-names>T</given-names></name><name><surname>Shirai</surname><given-names>T</given-names></name><name><surname>Kajimoto</surname><given-names>Y</given-names></name><name><surname>Kajimoto</surname><given-names>O</given-names></name><article-title>L-ornithine supplementation attenuates physical fatigue in healthy volunteers by modulating lipid and amino acid metabolism</article-title><source>Nutr Res</source><year>2008</year><volume>28</volume><fpage>738</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1016/j.nutres.2008.08.008</pub-id><pub-id pub-id-type="pmid">19083482</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Demura</surname><given-names>S</given-names></name><name><surname>Morishita</surname><given-names>K</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Yamaji</surname><given-names>S</given-names></name><name><surname>Komatsu</surname><given-names>M</given-names></name><article-title>Effect of L: -ornithine hydrochloride ingestion on intermittent maximal anaerobic cycle ergometer performance and fatigue recovery after exercise</article-title><source>Eur J Appl Physiol</source><year>2011</year><volume>111</volume><fpage>2837</fpage><lpage>2843</lpage><pub-id pub-id-type="doi">10.1007/s00421-011-1896-1</pub-id><pub-id pub-id-type="pmid">21431425</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="book"><name><surname>McNair</surname><given-names>P</given-names></name><name><surname>Lorr</surname><given-names>M</given-names></name><name><surname>Droppleman</surname><given-names>L</given-names></name><source>Profile of Mood States</source><year>1992</year><publisher-name>San Diego: Educational and Industrial Testing Service</publisher-name></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Soldatos</surname><given-names>CR</given-names></name><name><surname>Dikeos</surname><given-names>DG</given-names></name><name><surname>Paparrigopoulos</surname><given-names>TJ</given-names></name><article-title>Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria</article-title><source>J Psychosom Res</source><year>2000</year><volume>48</volume><fpage>555</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1016/S0022-3999(00)00095-7</pub-id><pub-id pub-id-type="pmid">11033374</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Takase</surname><given-names>M</given-names></name><name><surname>Shirakawa</surname><given-names>S</given-names></name><article-title>Standardization of revised version of OSA sleep inventory for middle age and aged</article-title><source>Brain Sci Ment Disord</source><year>1999</year><volume>10</volume><fpage>401</fpage><lpage>409</lpage></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Kurauchi</surname><given-names>I</given-names></name><name><surname>Shigemi</surname><given-names>K</given-names></name><name><surname>Kabuki</surname><given-names>Y</given-names></name><name><surname>Hamasu</surname><given-names>K</given-names></name><name><surname>Yamane</surname><given-names>H</given-names></name><name><surname>Aoki</surname><given-names>M</given-names></name><name><surname>Kawada</surname><given-names>Y</given-names></name><name><surname>Morishita</surname><given-names>K</given-names></name><name><surname>Denbow</surname><given-names>DM</given-names></name><name><surname>Furuse</surname><given-names>M</given-names></name><article-title>Central L-ornithine, but not polyamines, induces a hypnotic effect in neonatal chicks under acute stress</article-title><source>Nutr Neurosci</source><year>2010</year><volume>13</volume><fpage>17</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1179/147683010X12611460763481</pub-id><pub-id pub-id-type="pmid">20132650</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Kurata</surname><given-names>K</given-names></name><name><surname>Shigemi</surname><given-names>K</given-names></name><name><surname>Tomonaga</surname><given-names>S</given-names></name><name><surname>Aoki</surname><given-names>M</given-names></name><name><surname>Morishita</surname><given-names>K</given-names></name><name><surname>Denbow</surname><given-names>DM</given-names></name><name><surname>Furuse</surname><given-names>M</given-names></name><article-title>L-ornithine attenuates corticotropin-releasing factor-induced stress responses acting at GABAA receptors in neonatal chicks</article-title><source>Neuroscience</source><year>2011</year><volume>172</volume><fpage>226</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">21056090</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Suenaga</surname><given-names>R</given-names></name><name><surname>Yamane</surname><given-names>H</given-names></name><name><surname>Tomonaga</surname><given-names>S</given-names></name><name><surname>Asechi</surname><given-names>M</given-names></name><name><surname>Adachi</surname><given-names>N</given-names></name><name><surname>Tsuneyoshi</surname><given-names>Y</given-names></name><name><surname>Kurauchi</surname><given-names>I</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Denbow</surname><given-names>DM</given-names></name><name><surname>Furuse</surname><given-names>M</given-names></name><article-title>Central L-arginine reduced stress responses are mediated by L-ornithine in neonatal chicks</article-title><source>Amino Acids</source><year>2008</year><volume>35</volume><fpage>107</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1007/s00726-007-0617-x</pub-id><pub-id pub-id-type="pmid">18219550</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Cullinan</surname><given-names>WE</given-names></name><name><surname>Ziegler</surname><given-names>DR</given-names></name><name><surname>Herman</surname><given-names>JP</given-names></name><article-title>Functional role of local GABAergic influences on the HPA axis</article-title><source>Brain Struct Funct</source><year>2008</year><volume>213</volume><fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1007/s00429-008-0192-2</pub-id><pub-id pub-id-type="pmid">18696110</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Sarkar</surname><given-names>J</given-names></name><name><surname>Wakefield</surname><given-names>S</given-names></name><name><surname>MacKenzie</surname><given-names>G</given-names></name><name><surname>Moss</surname><given-names>SJ</given-names></name><name><surname>Maguire</surname><given-names>J</given-names></name><article-title>Neurosteroidogenesis is required for the physiological response to stress: role of neurosteroid-sensitive GABAA receptors</article-title><source>J Neurosci</source><year>2011</year><volume>31</volume><fpage>18198</fpage><lpage>18210</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2560-11.2011</pub-id><pub-id pub-id-type="pmid">22171026</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Dubrovsky</surname><given-names>B</given-names></name><article-title>Natural steroids counteracting some actions of putative depressogenic steroids on the central nervous system: potential therapeutic benefits</article-title><source>Med Hypotheses</source><year>1997</year><volume>49</volume><fpage>51</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/S0306-9877(97)90252-8</pub-id><pub-id pub-id-type="pmid">9247908</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Hechter</surname><given-names>O</given-names></name><name><surname>Grossman</surname><given-names>A</given-names></name><name><surname>Chatterton</surname><given-names>RT</given-names><suffix>Jr</suffix></name><article-title>Relationship of dehydroepiandrosterone and cortisol in disease</article-title><source>Med Hypotheses</source><year>1997</year><volume>49</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/S0306-9877(97)90258-9</pub-id><pub-id pub-id-type="pmid">9247914</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Goodyer</surname><given-names>IM</given-names></name><name><surname>Herbert</surname><given-names>J</given-names></name><name><surname>Altham</surname><given-names>PM</given-names></name><name><surname>Pearson</surname><given-names>J</given-names></name><name><surname>Secher</surname><given-names>SM</given-names></name><name><surname>Shiers</surname><given-names>HM</given-names></name><article-title>Adrenal secretion during major depression in 8- to 16-year-olds, I. Altered diurnal rhythms in salivary cortisol and dehydroepiandrosterone (DHEA) at presentation</article-title><source>Psychol Med</source><year>1996</year><volume>26</volume><fpage>245</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1017/S0033291700034644</pub-id><pub-id pub-id-type="pmid">8685281</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Ritsner</surname><given-names>M</given-names></name><name><surname>Maayan</surname><given-names>R</given-names></name><name><surname>Gibel</surname><given-names>A</given-names></name><name><surname>Strous</surname><given-names>RD</given-names></name><name><surname>Modai</surname><given-names>I</given-names></name><name><surname>Weizman</surname><given-names>A</given-names></name><article-title>Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients</article-title><source>Eur Neuropsychopharmacol</source><year>2004</year><volume>14</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2003.09.003</pub-id><pub-id pub-id-type="pmid">15163435</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="book"><name><surname>Miller</surname><given-names>WR</given-names></name><name><surname>Rollnick</surname><given-names>S</given-names></name><person-group person-group-type="editor">Miller WR, Rollnick S</person-group><article-title>Conversation about Change</article-title><source>Motivational Interviewing. Chapter 1</source><year>2012</year><publisher-name>New York: Guilford Press</publisher-name><fpage>3</fpage><lpage>13</lpage></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="book"><name><surname>Prochaska</surname><given-names>JO</given-names></name><name><surname>Norcross</surname><given-names>JC</given-names></name><person-group person-group-type="editor">Prochaska JO, Norcross JC</person-group><article-title>Defining and Comparing the Psychotherapies</article-title><source>Systems of Psychotherapy. Chapter 1</source><year>2007</year><publisher-name>Belmont: Thompson</publisher-name><fpage>1</fpage><lpage>24</lpage></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Korunka</surname><given-names>C</given-names></name><name><surname>Huemer</surname><given-names>KH</given-names></name><name><surname>Litschauer</surname><given-names>B</given-names></name><name><surname>Karetta</surname><given-names>B</given-names></name><name><surname>Kafka-Lutzow</surname><given-names>A</given-names></name><article-title>Working with new technologies: hormone excretion as an indicator for sustained arousal. A pilot study</article-title><source>Biol Psychol</source><year>1996</year><volume>42</volume><fpage>439</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1016/0301-0511(95)05172-4</pub-id><pub-id pub-id-type="pmid">8652758</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Kokubo</surname><given-names>T</given-names></name><name><surname>Ikeshima</surname><given-names>E</given-names></name><name><surname>Komatsu</surname><given-names>M</given-names></name><name><surname>Kirisako</surname><given-names>T</given-names></name><name><surname>Miura</surname><given-names>Y</given-names></name><name><surname>Horiuchi</surname><given-names>M</given-names></name><name><surname>Tsuda</surname><given-names>A</given-names></name><article-title>L-ornithine-L-aspartate improves alcohol-derived fatigue feeling in flushers</article-title><source>Jpn Pharmachol Ther</source><year>2012</year><volume>40</volume><fpage>205</fpage><lpage>212</lpage></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Omori</surname><given-names>K</given-names></name><name><surname>Kagami</surname><given-names>Y</given-names></name><name><surname>Yokoyama</surname><given-names>C</given-names></name><name><surname>Moriyama</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>N</given-names></name><name><surname>Masaki</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Kamasaka</surname><given-names>H</given-names></name><name><surname>Shiraishi</surname><given-names>K</given-names></name><name><surname>Kometani</surname><given-names>T</given-names></name><name><surname>Kuriki</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>ZL</given-names></name><name><surname>Urade</surname><given-names>Y</given-names></name><article-title>Promotion of non&#x02013;rapid eye movement sleep in mice after oral administration of ornithine</article-title><source>Sleep Biol Rhythms</source><year>2012</year><volume>10</volume><fpage>38</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1111/j.1479-8425.2011.00515.x</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Demura</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Yamaji</surname><given-names>S</given-names></name><name><surname>Komatsu</surname><given-names>M</given-names></name><name><surname>Morishita</surname><given-names>K</given-names></name><article-title>The effect of L-ornithine hydrochloride ingestion on performance during incremental exhaustive ergometer bicycle exercise and ammonia metabolism during and after exercise</article-title><source>Eur J Clin Nutr</source><year>2010</year><volume>64</volume><fpage>1166</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.1038/ejcn.2010.149</pub-id><pub-id pub-id-type="pmid">20717126</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Jeevanandam</surname><given-names>M</given-names></name><name><surname>Holaday</surname><given-names>NJ</given-names></name><name><surname>Petersen</surname><given-names>SR</given-names></name><article-title>Ornithine-alpha-ketoglutarate (OKG) supplementation is more effective than its component salts in traumatized rats</article-title><source>J Nutr</source><year>1996</year><volume>126</volume><fpage>2141</fpage><lpage>2150</lpage><pub-id pub-id-type="pmid">8814202</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Van Cauter</surname><given-names>E</given-names></name><name><surname>Plat</surname><given-names>L</given-names></name><name><surname>Copinschi</surname><given-names>G</given-names></name><article-title>Interrelations between sleep and the somatotropic axis</article-title><source>Sleep</source><year>1998</year><volume>21</volume><fpage>553</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">9779515</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Davidson</surname><given-names>JR</given-names></name><name><surname>Moldofsky</surname><given-names>H</given-names></name><name><surname>Lue</surname><given-names>FA</given-names></name><article-title>Growth hormone and cortisol secretion in relation to sleep and wakefulness</article-title><source>J Psychiatry Neurosci</source><year>1991</year><volume>16</volume><fpage>96</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">1911740</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Prinz</surname><given-names>PN</given-names></name><name><surname>Roehrs</surname><given-names>TA</given-names></name><name><surname>Vitaliano</surname><given-names>PP</given-names></name><name><surname>Linnoila</surname><given-names>M</given-names></name><name><surname>Weitzman</surname><given-names>ED</given-names></name><article-title>Effect of alcohol on sleep and nighttime plasma growth hormone and cortisol concentrations</article-title><source>J Clin Endocrinol Metab</source><year>1980</year><volume>51</volume><fpage>759</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1210/jcem-51-4-759</pub-id><pub-id pub-id-type="pmid">7419664</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Harada</surname><given-names>T</given-names></name><name><surname>Hirotani</surname><given-names>M</given-names></name><name><surname>Maeda</surname><given-names>M</given-names></name><name><surname>Nomura</surname><given-names>H</given-names></name><name><surname>Takeuchi</surname><given-names>H</given-names></name><article-title>Correlation between breakfast tryptophan content and morning-evening in Japanese infants and students aged 0&#x02013;15 yrs</article-title><source>J Physiol Anthropol</source><year>2007</year><volume>26</volume><fpage>201</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.2114/jpa2.26.201</pub-id><pub-id pub-id-type="pmid">17435366</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><name><surname>Kohyama</surname><given-names>J</given-names></name><article-title>Sleep, serotonin, and suicide in Japan</article-title><source>J Physiol Anthropol</source><year>2011</year><volume>30</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.2114/jpa2.30.1</pub-id><pub-id pub-id-type="pmid">21307614</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><name><surname>Paredes</surname><given-names>SD</given-names></name><name><surname>Marchena</surname><given-names>AM</given-names></name><name><surname>Bejarano</surname><given-names>I</given-names></name><name><surname>Espino</surname><given-names>J</given-names></name><name><surname>Barriga</surname><given-names>C</given-names></name><name><surname>Rial</surname><given-names>RV</given-names></name><name><surname>Reiter</surname><given-names>RJ</given-names></name><name><surname>Rodriguez</surname><given-names>AB</given-names></name><article-title>Melatonin and tryptophan affect the activity-rest rhythm, core and peripheral temperatures, and interleukin levels in the ringdove: changes with age</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2009</year><volume>64</volume><fpage>340</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">19211547</pub-id></mixed-citation></ref></ref-list></back></article>